The efficacy and safety of lyophilized cryoprecipitate in hemophilia A

Journal of the Medical Association of Thailand

Volumn 82, Issue SUPPL., 1999, Pages

  Chuansumrit, Ampaiwan ^a   Isarangkura, Parttraporn ^a   Chantanakajornfung, Aroonrat ^b   Kuhathong, Kesanee ^a   Pintadit, Pakaimas ^a   Jitpraphai, Chattaya ^a   Hathirat, Phongjan ^a   Nuchprayoon, Chaivej ^b  

^a MAHIDOL UNIVERSITY   (Thailand)

^b THAI RED CROSS AIDS RESEARCH CENTRE   (Thailand)

Author keywords

Efficacy; Hemophilia; Lyophilized Cryoprecipitate; Safety

Indexed keywords

BLOOD CLOTTING FACTOR 8;

ADOLESCENT; ADULT; ARTICLE; CHILD; FREEZE DRYING; HEMOPHILIA A; HUMAN; INFANT; PRESCHOOL CHILD; PROSPECTIVE STUDY; VIRUS ACTIVATION;

ADOLESCENT; ADULT; CHILD; CHILD, PRESCHOOL; FACTOR VIII; FREEZE DRYING; HEMOPHILIA A; HUMANS; INFANT; PROSPECTIVE STUDIES; VIRUS ACTIVATION;

EID: 0042211211     PISSN: 01252208     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (15)

1. Isarangkura P, Chuansumrit A, Hathirat P, et al. HIV seroconversion in Thai hemophiliacs up to 1991. Southeast Asian J Trop Med Pub Hlth 1993; 24 (Suppl 1):191-4.
2. Hardisty RM, Macphersen JC. A one-stage factor VIII (antihaemophilic globulin) assay and its use on venous blood and capillary plasma. Thromb Diath Haemorrh 1962; 7:215-28.
3. Kasper CK, Aledort LM, Counts RB, et al. A more uniform measurement of factor VIII inhibitors. Thromb Diath Haemorrh 1975; 34:869-72.
4. Skjonsberg OH, Gravem K, Kierulf P, Godal HC. Characteristics of a heat-treated antihemophilic cryoprecipitate. Thromb Res 1987; 45:625-34.
5. Skjonsberg OH, Gravem K, Kierulf P, Varat A, Godal HC. The influence of pH on heat denaturation of antihemophilic cryoprecipitate. Thromb Res1987; 47:183-90.
6. Carlsson M, Berntorp E, Bjorkman S, Lindvall K. Pharmacokinetic dosing in prophylactic treatment of hemophilia A. Eur J Haematol 1993; 51:247-52.
7. Matucci M, Messori A, Donati-Cori G, et al. Kinetic evaluation of four factor VIII concentrates by model independent methods. Scand J Haematol 1985; 34:22-8.
8. Messori A, Longo G, Matucci M, Morfini M, Rossi Ferrini PL. Clinical pharmacokinetics of factor VIII in patients with classic haemophilia. Clin Pharmacokin 1987; 13:365-80.
9. Messori A, Longo G, Morfini M, et al. Multivariate analysis of factor governing the pharmacokinetics of exogenous factor VIII in haemophiliacs. Eur J Clin Pharmacol 1988; 35:663-8.
10. Bjorkman S, Carlsson M, Berntorp E, Stenberg P. Pharmacokinetics of factor VIII in humans-obtaining clinically relevant data from comparative studies. Clin Pharmacokin 1992; 22:385-95.
11. Chuansumrit A, Isarangkura P, Hathirat P, Chiewsilp P, Kittikol J. Care of Thai hemophilia patients from 1969 to 1991. J Med Assoc Thai 1993; 76(Suppl 2):92-102.
12. Bloom AL. Progress in the clinical management of hemophilia. Thromb Haemostas 1991; 66:166-77.
13. Kruvacho T, Chuansumrit A, Isarangkura P, Pintadit P, Hathirat P, Chiewsilp P. Response of hemophilia A with bleeding to fresh dry plasma. Southeast Asian J Trop Med Pub Hlth 1993; 24 (Suppl 1):169-73.
14. Bresters D, Cuypers HTM, Reesink HW, et al. Enhanced sensitivity of a second-generation ELISA for antibody to hepatitis C virus. Vox Sang 1992; 62:213-7.
15. Morfini M, Mannucci PM, Ciavarella N, et al. Prevalence of infection with hepatitis C among Italian hemophiliacs before and after the introduction of virally inactivated clotting factor concentrates : a retrospective evaluation. Vox Sang 1994; 67:178-82.